The DOI matches its Crossref record; 27 of the 29 references it cites were found in a registry or an index.
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Abstract
Background Nanoliposomal irinotecan showed activity in a phase 2 study in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapies. We assessed the effect of nanoliposomal irinotecan alone or combined with fluorouracil and folinic acid in a phase 3 trial in this population.Methods We did a global, phase 3, randomised, open-label trial at 76 sites in 14 countries. Eligible patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy were randomly assigned (1:1) using an interactive web response system at a central location to receive either nanoliposomal irinotecan monotherapy (120 mg/m(2) every 3 weeks, equivalent to 100 mg/m(2) of irinotecan base) or fluorouracil and folinic acid. A third arm consisting of nanoliposomal irinotecan (80 mg/m(2), equivalent to 70 mg/m(2) of irinotecan base) with fluorouracil and folinic acid every 2 weeks was added later (1:1:1), in a protocol amendment. Randomisation was stratified by baseline albumin, Karnofsky performance status, and ethnic origin. Treatment was continued until disease progression or intolerable toxic effects. The primary endpoint was overall survival, assessed in the intention-to-treat population. The primary analysis was planned after 305 events. Safety was assessed in all patients who had received study drug. This trial is registered at ClinicalTrials.gov, number NCT01494506.Findings Between Jan 11, 2012, and Sept 11, 2013, 417 patients were randomly assigned either nanoliposomal irinotecan plus fluorouracil and folinic acid (n=117), nanoliposomal irinotecan monotherapy (n=151), or fluorouracil and folinic acid (n=149). After 313 events, median overall survival in patients assigned nanoliposomal irinotecan plus fluorouracil and folinic acid was 6.1 months (95% CI 4.8-8.9) vs 4.2 months (3.3-5.3) with fluorouracil and folinic acid (hazard ratio 0.67, 95% CI 0.49-0.92; p=0.012). Median overall survival did not differ between patients assigned nanoliposomal irinotecan monotherapy and those allocated fluorouracil and folinic acid (4.9 months [4.2-5.6] vs 4.2 months [3.6-4.9]; 0.99, 0.77-1.28; p=0.94). The grade 3 or 4 adverse events that occurred most frequently in the 117 patients assigned nanoliposomal irinotecan plus fluorouracil and folinic acid were neutropenia (32 [27%]), diarrhoea (15 [13%]), vomiting (13 [11%]), and fatigue (16 [14%]).Interpretation Nanoliposomal irinotecan in combination with fluorouracil and folinic acid extends survival with a manageable safety profile in patients with metastatic pancreatic ductal adenocarcinoma who previously received gemcitabine-based therapy. This agent represents a new treatment option for this population.Funding Merrimack Pharmaceuticals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients progressing on first-line regimens can be offered the possibility of switching to the other regimen, or a second-line regimen that includes a liposomal formulation of irinotecan in combination with 5-FU10, provided they have not received either of these agents previously.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [10]
Citations
Cites
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Self-citationIncreased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Self-citationBurris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Oettle, H., Riess, H. B., Stieler, J., Heil, G., Schwaner, I., Seraphin, J., Görner, M., Mölle, M., Greten, T. F., Lakner, V., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6995 · Cited by 492
Self-citationKalra, A. V., Kim, J., Klinz, S. G., Paz, N., Cain, J. E., Drummond, D. C., Nielsen, U. B., & Fitzgerald, J. B. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0572 · Cited by 199
Self-citationPharmacogenetics of irinotecan metabolism and transport: An update
Smith, N. F., Figg, W. D., & Sparreboom, A. (2005) · Toxicology in Vitro · doi:10.1016/j.tiv.2005.06.045 · Cited by 190
Yoo, C., Hwang, J. Y., Kim, J. H., Kim, T. W., Lee, J. S., Park, D. H., Lee, S. K., Seo, D. W., Lee, S. S., Kim, M., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605374 · Cited by 169
Self-citationKo, A. H., Tempero, M. A., Shan, Y.-S., Su, W., Lin, Y.-L., Dito, E., Ong, A., Wang, Y.-W., Yeh, C. G., & Chen, L.-T. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.408 · Cited by 160
Self-citationRoy, A. C., Park, S. R., Cunningham, D., Kang, Y., Chao, Y., Chen, L., Rees, C., Lim, H. Y., Tabernero, J. M., Ramos, F. J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt002 · Cited by 123
Self-citation
Cited by
Sorted by citations
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586
Mizrahi, J. D., Surana, R., Valle, J. W., & Shroff, R. T. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30974-0 · Cited by 2,559
Liposomal Formulations in Clinical Use: An Updated Review
Bulbake, U., Doppalapudi, S., Kommineni, N., & Khan, W. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9020012 · Cited by 2,174
“5 months for those who consumed either fluorouracil or leucovorin [45].”
BackgroundKleeff, J., Korc, M., Apte, M., La Vecchia, C., Johnson, C. D., Biankin, A. V., Neale, R. E., Tempero, M., Tuveson, D. A., Hruban, R. H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.22 · Cited by 1,982
Park, W., Chawla, A., & O'Reilly, E. M. (2021) · JAMA · doi:10.1001/jama.2021.13027 · Cited by 2,040
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A. E., ELIAS, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,612
Pancreatic cancer: Advances and challenges
Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Tempero, M. A., Malafa, M. P., Al-Hawary, M. M., Behrman, S. W., Benson, A. B., Cardin, D. B., Chiorean, E. G., Chung, V. M., Czito, B. G., Chiaro, M. D., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0017 · Cited by 1,356
“Grade 3 or 4 adverse events that occurred most frequently with this regimen were neutropenia (27%), fatigue (14%), diarrhea (13%), and vomiting (11%).(205) Irinotecan liposomal injection, combined with 5-FU/leucovorin, was later approved by the FDA to be used as a subsequent treatment option after gemcitabinebased the…”
BackgroundMethodSelf-citationTherapeutic developments in pancreatic cancer: current and future perspectives
Neoptolemos, J. P., Kleeff, J., Michl, P., Costello, E., Greenhalf, W., & Palmer, D. H. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0005-x · Cited by 1,170
Self-citationvan der Meel, R., Sulheim, E., Shi, Y., Kiessling, F. M., Mulder, W. J. M., & Lammers, T. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0567-y · Cited by 1,279
Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Tempero, M. A., Malafa, M. P., Al-Hawary, M. M., Asbun, H. J., Bain, A. J., Behrman, S. W., Benson, A. B., Binder, E. F., Cardin, D. B., Cha, C. H., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0131 · Cited by 1,037
Self-citationCancer nanomedicine: A review of recent success in drug delivery
Tran, S., DeGiovanni, P., Piel, B., & Rai, P. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0175-0 · Cited by 879
“survival with nanoliposomal irinotecan monotherapy versus fluorouracil and folinic acid (Reproduced with permission from [77])”
BackgroundMethodPancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Conroy, T., Pfeiffer, P., Vilgrain, V., Lamarca, Á., Seufferlein, T. T. W., O'Reilly, E. M., Hackert, T., Golan, T., Prager, G. W., Haustermans, K. M., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.08.009 · Cited by 706
Self-citationLiposomal Drug Delivery Systems and Anticancer Drugs
Olusanya, T. O. B., Haj-Ahmad, R., Ibegbu, M. D., Smith, J. R., & Elkordy, A. (2018) · Molecules · doi:10.3390/molecules23040907 · Cited by 605
“Irinotecan Pancreatic ductal adenocarcinoma [100]”
BackgroundBockorny, B., Semenisty, V., Macarulla, T. M., Borazanci, E. H., Wolpin, B. M., Stemmer, S. M., Golan, T., Geva, R., Borad, M. J., Pedersen, K. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0880-x · Cited by 563
Self-citationWainberg, Z. A., Melisi, D., Macarulla, T. M., Pazo-Cid, R., Chandana, S. R., de la Fouchardière, C., Dean, A. P., Kišš, I., Lee, W. J., Goetze, T. O., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01366-1 · Cited by 548
Self-citationLipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment
García-Pinel, B., Porras-Alcalá, C., Ortega-Rodríguez, A., Sarabia, F., Prados, J. C., Melguizo, C., & López‐Romero, J. M. (2019) · Nanomaterials · doi:10.3390/nano9040638 · Cited by 530
Nanomedicine review: clinical developments in liposomal applications
Beltran-Gracia, E., López-Camacho, A., Higuera‐Ciapara, I., Velázquez-Fernández, J. B., & Vallejo‐Cardona, A. A. (2019) · Cancer Nanotechnology · doi:10.1186/s12645-019-0055-y · Cited by 544
Stoop, T. F., Javed, A. A., Oba, A., Koerkamp, B. G., Seufferlein, T. T. W., Wilmink, J. W., & Besselink, M. G. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00261-2 · Cited by 601
Self-citationMultidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma
Grossberg, A. J., Chu, L. C. H., Deig, C. R., Fishman, E. K., Hwang, W. L., Maitra, A., Marks, D. L., Mehta, A., Nabavizadeh, N., Simeone, D. M., et al. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21626 · Cited by 500
Therapeutic developments in pancreatic cancer
Hu, Z., & O'Reilly, E. M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00840-w · Cited by 438
Choi, Y. H., & Han, H. (2017) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-017-0370-4 · Cited by 408
“The FDA approved 51 nanomedicines by the year 2016, 40% of which were in clinical trials between 2014 and 2016 (Arnold et al. 2001; Benbrook 2015; Berges and Eligard 2005; Bobo et al. 2016; Desai et al. 2006; Duncan 2014; FDA 2006, 2014, 2015; Foss 2006; Foss et al. 2013; Fuentes et al. 2015; Green et al. 2006; Hann a…”
BackgroundPancreatic Cancer: A Review of Current Treatment and Novel Therapies
Kolbeinsson, H. M., Chandana, S. R., Wright, G. P., & Chung, M. H. (2022) · Journal of Investigative Surgery · doi:10.1080/08941939.2022.2129884 · Cited by 433
“After progression on first-line gemcitabine-based therapy, nanoliposomal irinotecan in combination with 5FU compared to 5FU alone was shown in the NAPOLI-1 study to have survival advantage of a mOS of 6.1 months vs 4.2 months) in PDAC patients [58].”
InfluentialWang, S., Zheng, Y., Yang, F., Zhu, L., Zhu, X.-Q., Wang, Z.-F., Wu, X.-L., Zhou, C.-H., Yan, J.-Y., Hu, B.-Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00659-4 · Cited by 369
Targeting Topoisomerase I in the Era of Precision Medicine
Thomas, A., & Pommier, Y. G. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1089 · Cited by 345
“Despite the pharmacokinetic benefits anddelivery advantage, diarrheaoccurs frequently and is severe or life-threatening in 20% of the cases (44).”
BackgroundWang-Gillam, A., Hubner, R. A., Siveke, J. T., Von Hoff, D. D., Belanger, B., de Jong, F. A., Mirakhur, B., & Chen, L.-T. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.007 · Cited by 342
Self-citationMicroenvironmental Determinants of Pancreatic Cancer
Heßmann, E., Buchholz, S., Demir, İ. E., Singh, S. K., Gress, T. M., Ellenrieder, V., & Neeße, A. (2020) · Physiological Reviews · doi:10.1152/physrev.00042.2019 · Cited by 336
Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Sohal, D. P. S., Mangu, P. B., Khorana, A. A., Shah, M. A., Philip, P. A., O'Reilly, E. M., Uronis, H. E., Ramanathan, R. K., Crane, C. H., Engebretson, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1412 · Cited by 339
“of modified approaches to FOLFIRINOX and gemcitabine plus NAB-paclitaxel use.(39,40) The treating physician’s judgment remains”
MethodThe Multirole of Liposomes in Therapy and Prevention of Infectious Diseases
Nisini, R., Poerio, N., Mariotti, S., Santis, F. D., & Fraziano, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00155 · Cited by 308
“OnivydeTM Irinotecan Multilamellar vesicles Metastatic adenocarcinoma of the pancreas (48)”
BackgroundLammers, T. (2024) · Advanced Materials · doi:10.1002/adma.202312169 · Cited by 311
Gill, S., Ko, Y., Cripps, C., Beaudoin, A., Dhesy‐Thind, S., Zulfiqar, M., Zalewski, P., Do, T., Cano, P., Lam, W. Y. H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.5776 · Cited by 292
“Interestingly, for the secondary end point of OS, a more favorable OSwas observed in patients randomly assigned to infusional FU/LV.”
BackgroundInfluentialChemotherapy for pancreatic cancer
Springfeld, C., Jäger, D., Büchler, M. W., Strobel, O., Hackert, T., Palmer, D. H., & Neoptolemos, J. P. (2019) · La Presse Médicale · doi:10.1016/j.lpm.2019.02.025 · Cited by 297
Self-citationMetastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update
Sohal, D. P. S., Kennedy, E. B., Khorana, A. A., Copur, M. S., Crane, C. H., Garrido‐Laguna, I., Krishnamurthi, S., Moravek, C., O'Reilly, E. M., Philip, P. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9636 · Cited by 279
Pishvaian, M. J., Bender, R. J., Halverson, D., Rahib, L., Hendifar, A. E., Mikhail, S., Chung, V., Picozzi, V. J., Sohal, D., Blais, E. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0531 · Cited by 245
“4 months, which is comparable with historical controls derived from a trial of nanoliposomal irinotecan plus 5-fluorouracil [NAPOLI-1 trial (28): median PFS in experimental arm 1⁄4 3.”
BackgroundSelf-citationWhat Went Wrong with Anticancer Nanomedicine Design and How to Make It Right
Sun, D., Zhou, S. Y., & Gao, W. (2020) · ACS Nano · doi:10.1021/acsnano.9b09713 · Cited by 273
Le, D. T., Picozzi, V. J., Ko, A. H., Wainberg, Z. A., Kindler, H. L., Wang‐Gillam, A., Oberstein, P. E., Morse, M. A., Zeh, H. J., Weekes, C. D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2992 · Cited by 266
“This is in contrast to the NAPOLI-1 trial, whichwas a global studywhere 90%of patients randomized to the fluorouracil/folinic acid arm received study assigned treatment despite 70% of these patients having received only 1 prior therapy for metastatic disease (3).”
ResultSelf-citationThe Immune Microenvironment in Pancreatic Cancer
Huber, M., Brehm, C. U., Gress, T. M., Buchholz, M., Alhamwe, B. A., von Strandmann, E. P., Slater, E. P., Bartsch, J. W., Bauer, C. A., & Lauth, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197307 · Cited by 250
Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer
Adiseshaiah, P. P., Crist, R. M., Hook, S. S., & McNeil, S. E. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.119 · Cited by 239
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
Qi, C., Liu, C., Gong, J., Liu, D., Wang, X., Zhang, P., Qin, Y., Ge, S., Zhang, M., Peng, Z., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03037-z · Cited by 235
Liu, X., Lin, P. K., Perrett, I., Lin, J., Liao, Y., Chang, C. H., Jiang, J., Wu, N., Donahue, T. R., Wainberg, Z. A., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92284 · Cited by 229
“However, no detailed investigation of the PDAC transcytosis pathway has been undertaken, and it is unknown whether it could be beneficial from the perspective of iRGD peptide coadministration to further enhance the nanocarrier OS effects (7, 8).”
BackgroundJi, T., Lang, J., Wang, J., Cai, R., Zhang, Y., Qi, F., Zhang, L., Zhao, X. L., Wu, W., Hao, J., et al. (2017) · ACS Nano · doi:10.1021/acsnano.7b01026 · Cited by 222
Yoo, C., Kim, K., Jeong, J. H., Kim, I. H., Kang, M. J., Cheon, J., Kang, B. W., Ryu, H., Lee, J. S., Kim, K. W., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00486-1 · Cited by 222
Recent advances and clinical translation of liposomal delivery systems in cancer therapy
Chen, J., Hu, S., Sun, M., Shi, J., Zhang, H., Yu, H., & Yang, Z. (2024) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106688 · Cited by 233
Self-citationCheckpoint inhibitors in pancreatic cancer
Henriksen, A., Dyhl-Polk, A., Chen, I. M., & Nielsen, D. L. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.06.005 · Cited by 219
Pant, S., Schuler, M., Iyer, G., Witt, O., Doi, T., Qin, S., Tabernero, J. M., Reardon, D. A., Massard, C., Minchom, A., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00275-9 · Cited by 217
Self-citationAn update on treatment options for pancreatic adenocarcinoma
Lambert, A., Schwarz, L., Borbath, I., Henry, A., Laethem, J. V., Malka, D., Ducreux, M. P., & Conroy, T. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919875568 · Cited by 222
Treatment landscape of metastatic pancreatic cancer
Dosso, S. D., Siebenhüner, A. R., Winder, T., Meisel, A., Fritsch, R., Astaras, C., Szturz, P., & Borner, M. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102180 · Cited by 212
Neuzillet, C., Gaujoux, S., Williet, N., Bachet, J., Bauguion, L., Durand, L. C., Conroy, T., Dahan, L., Gilabert, M., Huguet, F., et al. (2018) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.08.008 · Cited by 222
Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study
Kamath, S. D., Kalyan, A., Kircher, S. M., Nimeiri, H. S., Fought, A. J., Benson, A. B., & Mulcahy, M. F. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0473 · Cited by 200
“1 months seen in the NAPOLI-1 study of 5-FU and nanoliposomal irinotecan in a similar advanced pancreatic cancer population who had received prior gemcitabine-based chemotherapy [24].”
BackgroundCurrent standards and new innovative approaches for treatment of pancreatic cancer
Conroy, T., Bachet, J., Ayav, A., Huguet, F., Lambert, A., Caramella, C., Maréchal, R., Laethem, J. V., & Ducreux, M. P. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.12.026 · Cited by 193
“2 months), PFS and Objective Response Rate (ORR) in the intent-to-treat population over fluorouracil/folinic acid alone [80].”
BackgroundLiposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs
Milano, G. A., Innocenti, F., & Minami, H. (2022) · Cancer Science · doi:10.1111/cas.15377 · Cited by 184
Membrane‐destabilizing ionizable lipid empowered imaging‐guided siRNA delivery and cancer treatment
Guo, S., Li, K., Hu, B., Li, C., Zhang, M., Hussain, A., Wang, X., Cheng, Q., Yang, F., Ge, K., et al. (2021) · Exploration · doi:10.1002/exp.20210008 · Cited by 176
Self-citationRucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
Shroff, R. T., Hendifar, A. E., McWilliams, R. R., Geva, R., Epelbaum, R., Rolfe, L., Goble, S. M., Lin, K., Biankin, A. V., Giordano, H., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00316 · Cited by 183
Biological Effects of Nanoparticles on Macrophage Polarization in the Tumor Microenvironment
Reichel, D., Tripathi, M., & Perez, J. M. (2018) · Nanotheranostics · doi:10.7150/ntno.30052 · Cited by 178
Pancreas Cancer-Associated Weight Loss
Hendifar, A. E., Petzel, M. Q. B., Zimmers, T. A., Denlinger, C. S., Matrisian, L. M., Picozzi, V. J., & Rahib, L. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0266 · Cited by 178
“Additionally, current chemotherapy regimens, including gemcitabine/nabpaclitaxel [40], FOLIFIRINOX [41], and nanoliposomal irinotecan/5FU [42], can cause nausea, vomiting, indigestion, Figure 1.”
BackgroundPiktel, E., Niemirowicz, K., Wątek, M., Wollny, T., Deptuła, P., & Bucki, R. (2016) · Journal of Nanobiotechnology · doi:10.1186/s12951-016-0193-x · Cited by 171
Photonanomedicine: a convergence of photodynamic therapy and nanotechnology
Obaid, G., Broekgaarden, M., Bulin, A., Huang, H., Kuriakose, J., Liu, J., & Hasan, T. G. (2016) · Nanoscale · doi:10.1039/c5nr08691d · Cited by 170
Ramanathan, R. K., Korn, R. L., Raghunand, N., Sachdev, J. C., Newbold, R. G., Jameson, G., Fetterly, G. J., Prey, J., Klinz, S. G., Kim, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1990 · Cited by 183
“Nal-IRI in combination with 5-fluorouracil/ leucovorin (5-FU/LV) is approved for use in the United States, EuropeanUnion, andTaiwanHealthAuthorities for the treatment of patients with metastatic pancreatic cancer after disease progression following gemcitabine-based therapy (11, 12).”
BackgroundInfluentialSelf-citationRedox/pH dual-stimuli responsive camptothecin prodrug nanogels for “on-demand” drug delivery
Qu, Y., Chu, B., Wei, X., Lei, M., Hu, D., Zha, R., Zhong, L. X., Wang, M., Wang, F., & Qian, Z. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.01.016 · Cited by 166
Liu, X., Jiang, J., & Meng, H. (2019) · Theranostics · doi:10.7150/thno.38587 · Cited by 164
“Recently, the FDA approved the use of GEM plus Albumin-bound paclitaxel nanocomplex (Abraxane) and liposomal irinotecan nanocarrier (Onivyde) plus fluorouracil for PDAC treatment, which lead to an improvement of overall survival of ~2 months[13, 14].”
BackgroundNew Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma
Singh, R., & O'Reilly, E. M. (2020) · Drugs · doi:10.1007/s40265-020-01304-0 · Cited by 158
“6), which was not different to 5-FU/LV [37].”
BackgroundTsujikawa, T., Crocenzi, T. S., Durham, J. N., Sugar, E. A., Wu, A. A., Onners, B., Nauroth, J. M., Anders, R. A., Fertig, E. J., Laheru, D. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3978 · Cited by 155
“org Clin Cancer Res; 26(14) July 15, 2020 3581”
BackgroundResultInfluentialPassero, F. C., Grapsa, D., Syrigos, K., & Saif, M. W. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1192471 · Cited by 152
“One of the 14 patients who received nanoliposomal irinotecan discontinued due to grade 3 vomiting and one patient required further dose reduction to 40 mg/m(2) [11].”
BackgroundArtificial intelligence in nanomedicine
Ho, D., Wang, P., & Kee, T. W. (2018) · Nanoscale Horizons · doi:10.1039/c8nh00233a · Cited by 158
Current and future therapies for advanced pancreatic cancer
Gupta, R., Amanam, I. U., & Chung, V. M. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24623 · Cited by 153
Self-citationCurrent and Emerging Therapies in Metastatic Pancreatic Cancer
Manji, G. A., Olive, K. P., Saenger, Y. M., & Oberstein, P. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2319 · Cited by 145
“In 2015, combination nanoliposomal irinotecan and 5-FU was the first regimen approved by the FDA for secondline therapy in PDAC (26).”
BackgroundiRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery
Kang, S., Lee, S., & Park, S. (2020) · Polymers · doi:10.3390/polym12091906 · Cited by 139
Barriers and opportunities for gemcitabine in pancreatic cancer therapy
Beutel, A. K., & Halbrook, C. J. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00331.2022 · Cited by 150
Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer
Schram, A. M., Goto, K., Kim, D., Macarulla, T. M., Hollebecque, A., O'Reilly, E. M., Ou, S. I., Rodon, J. A., Rha, S. Y., Nishino, K., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2405008 · Cited by 142
“22 Zenocutuzumab demonstrated promising activity in patients with pancreatic cancer, with a response rate of 42% and median duration of response of 7.4 months.”
InfluentialSelf-citationHuang, H., Mallidi, S., Liu, J., Chiang, C.-T., Mai, Z., Goldschmidt, R., Ebrahim-Zadeh, N., Rizvi, I., & Hasan, T. G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0391 · Cited by 141
Mehrotra, S., Britten, C. D., Chin, S. H., Garrett-Mayer, E. S., Cloud, C. A., Li, M., Scurti, G. M., Salem, M. L., Nelson, M. H., Thomas, M. B., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0459-2 · Cited by 140
“9 months observed with second line chemotherapy for metastatic pancreas cancer [64].”
BackgroundOvercoming Physiological Barriers to Nanoparticle Delivery—Are We There Yet?
Thomas, O. S., & Weber, W. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00415 · Cited by 146
“, 2009), potentially hampering the EPR effect [yet, a combination therapy of Onivyde plus 5-fluorouracil and leucovorin moderately improved overall survival in patients of metastatic pancreatic cancer (Wang-Gillam et al., 2016)].”
BackgroundRecent advances in engineered chitosan-based nanogels for biomedical applications
Wang, H., Qian, J., & Ding, F. (2017) · Journal of Materials Chemistry B · doi:10.1039/c7tb01624g · Cited by 133
Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies
Chiaravalli, M., Reni, M., & O'Reilly, E. M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.007 · Cited by 137
Liu, X., Jiang, J., Liao, Y., Tang, I., Zheng, E., Qiu, W., Lin, M. J., Wang, X., Ji, Y. C., Mei, K., et al. (2021) · Advanced Science · doi:10.1002/advs.202002147 · Cited by 129
Liu, X., Jiang, J., Chan, R., Ji, Y. C., Lu, J., Liao, Y., Okene, M. O., Lin, J., Lin, P. K., Chang, C. H., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b06164 · Cited by 128
Pancreatic cancer in 2021: What you need to know to win
Tonini, V., & Zanni, M. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i35.5851 · Cited by 133
Clinical applications of nanomedicine in cancer therapy
Norouzi, M., Amerian, M., Amerian, M., & Atyabi, F. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.09.017 · Cited by 126
Chemotherapy and tumor microenvironment of pancreatic cancer
Liu, Q., Liao, Q., & Zhao, Y. (2017) · Cancer Cell International · doi:10.1186/s12935-017-0437-3 · Cited by 120
“[25] reported nanoliposomal irinotecan in combination with fluorouracil and folinic acid significantly extended survival in patients with metastatic pancreatic cancer who previously received gemcitabine based therapy.”
BackgroundMetformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer
Chen, K., Qian, W., Jiang, Z., Cheng, L., Li, J., Sun, L., Zhou, C., Gao, L., Lei, M., Yan, B., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0701-0 · Cited by 125
“For those who present with metastatic pancreatic cancer and have received gemcitabine-based therapy previously, nanoliposomal irinotecan in combination with fluorouracil and folinic acid extends patients’ median overall survival [44].”
BackgroundEngineered Nanomaterials: The Challenges and Opportunities for Nanomedicines
Albalawi, F., Hussein, M. Z., Fakurazi, S., & Masarudin, M. J. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s288236 · Cited by 129
Recent Progress of Nanocarrier-Based Therapy for Solid Malignancies
Wei, Q.-Y., Xu, Y., & Lau, A. T. Y. (2020) · Cancers · doi:10.3390/cancers12102783 · Cited by 121
Current Standards of Chemotherapy for Pancreatic Cancer
Saung, M. T., & Zheng, L. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.08.015 · Cited by 122
“5-FU/Liposomal Irinotecan The regimen of 5-FU/liposomal irinotecan as a standard-of-care second-line therapy is supported by Level I evidence from the NAPOLI-1 trial.(27) In NAPOLI-1, an international Phase III study, patients with metastatic pancreatic cancer whose disease progressed on previous gemcitabine therapy w…”
Therapeutic resistance of pancreatic cancer: Roadmap to its reversal
Yu, S., Zhang, C., & Xie, K. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188461 · Cited by 119
Chen, I. M., Johansen, J. S., Theile, S., Hjaltelin, J. X., Novitski, S. I., Brunak, S., Hasselby, J. P., Willemoe, G. L., Lorentzen, T., Madsen, K. S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02511 · Cited by 118
“2 months seen when using FU/leucovorin in second-line therapies.(4) An average response rate of 10% can be achieved by the current second-line therapies for mPC.”
BackgroundHurwitz, H. I., Cutsem, E. V., Bendell, J. C., Hidalgo, M. M., Li, C., Salvo, M. G., Macarulla, T. M., Sahai, V., Sama, A. R., Greeno, E. W., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0580-2 · Cited by 113
Self-citationCAR T‐cell therapy for pancreatic cancer
DeSelm, C. J., Tano, Z. E., Varghese, A. M., & Adusumilli, P. S. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24627 · Cited by 116
Hammel, P. R., Portales, F., Mineur, L., Metges, J., André, T., de la Fouchardière, C., Louvet, C., Hajbi, F. E., Faroux, R., Guimbaud, R., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.10.020 · Cited by 114
“Thus, our results are consistent with those for nanoliposomal irinotecan and also with those in the gemcitabine postFOLFIRINOX setting [11,12].”
Advances in the management of pancreatic cancer
Chiaro, M. D., Sugawara, T., Karam, S. D., & Messersmith, W. A. (2023) · BMJ · doi:10.1136/bmj-2022-073995 · Cited by 118
Nanomaterial Preparation by Extrusion through Nanoporous Membranes
Guo, P., Huang, J., Zhao, Y., Martin, C. R., Zare, R. N., & Moses, M. A. (2018) · Small · doi:10.1002/smll.201703493 · Cited by 110
Topoisomerase I inhibitors: Challenges, progress and the road ahead
Talukdar, A., Kundu, B., Sarkar, D., Goon, S., & Mondal, M. A. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114304 · Cited by 115
Gemcitabine loaded microbubbles for targeted chemo-sonodynamic therapy of pancreatic cancer
Nesbitt, H., Sheng, Y., Kamila, S., Logan, K. A., Thomas, K. G., Callan, B., Taylor, M., Love, M., O’Rourke, D. M., Kelly, P., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.04.018 · Cited by 108
“Many of the drug-based treatments for pancreatic cancer involve Gem either as a stand-alone agent or in combination with other chemotherapies / radiotherapy [4].”
BackgroundLammers, T., & Mauro Ferrari, B. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100853 · Cited by 111
Developments in nanotechnology approaches for the treatment of solid tumors
Venturini, J., Chakraborty, A., Baysal, M. A., & Tsimberidou, A. M. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00656-1 · Cited by 123
“This formulation provided a sustained intratumoral release of irinotecan, thus prolonging the drug’s activity and improving patient outcomes [105].”
Photodynamic Priming Mitigates Chemotherapeutic Selection Pressures and Improves Drug Delivery
Huang, H., Rizvi, I., Liu, J., Anbil, S. R., Kalra, A. V., Lee, H., Baglo, Y., Paz, N., Hayden, D., Pereira, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1700 · Cited by 109
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
Frampton, J. E. (2020) · Drugs · doi:10.1007/s40265-020-01336-6 · Cited by 102
Taı̈eb, J., Sayah, L., Heinrich, K., Kunzmann, V., Boilève, A., Cirkel, G. A., Lonardi, S., Chibaudel, B., Turpin, A., Beller, T., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.04.012 · Cited by 103
Systemic treatment of pancreatic cancer revisited
Ducreux, M. P., Seufferlein, T. T. W., Laethem, J. V., Laurent‐Puig, P., Smolenschi, C., Malka, D., Boige, V., Hollebecque, A., & Conroy, T. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.12.003 · Cited by 105
Self-citationAnticancer nanoparticulate polymer‐drug conjugate
Feng, Q., & Tong, R. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10033 · Cited by 99
“[16] Wang-Gillam A, Li C-P, Bodoky G, et al.”
Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC)
Chandana, S. R., Babiker, H. M., & Mahadevan, D. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1557145 · Cited by 102
“the second line setting, after treatment with gemcitabinebased regimen [46].”
Background
Metadata
- Authors
- Wang-Gillam, A., Li, C.-P., Bodoky, G., Dean, A., Shan, Y.-S., Jameson, G., Macarulla, T., Lee, K.-H., Cunningham, D., Blanc, J. F., Hubner, R. A., Chiu, C.-F., Schwartsmann, G., Siveke, J. T., Braiteh, F., Moyo, V., Belanger, B., Dhindsa, N., Bayever, E., Von Hoff, D. D., Chen, L.-T., Adoo, C., Anderson, T., Asselah, J., Azambuja, A., Bampton, C., Barrios, C. H., Bekaii-Saab, T., Bohuslav, M., Chang, D., Chen, J.-S., Chen, Y.-C., Choi, H. J., Chung, I. J., Chung, V., Csoszi, T., Cubillo, A., DeMarco, L., de Wit, M., Dragovich, T., Edenfield, W., Fein, L. E., Franke, F., Fuchs, M., Gonzales-Cruz, V., Gozza, A., Fernando, R. H., Iaffaioli, R., Jakesova, J., Kahan, Z., Karimi, M., Kim, J. S., Korbenfeld, E., Lang, I., Lee, F.-C., Lee, K.-D., Lipton, L., Ma, W. W., Mangel, L., Mena, R., Palmer, D., Pant, S., Park, J. O., Piacentini, P., Pelzer, U., Plazas, J. G., Prasad, C., Rau, K.-M., Raoul, J.-L., Richards, D., Ross, P., Schlittler, L., Smakal, M., Stahalova, V., Sternberg, C., Seufferlein, T., Tebbutt, N., Vinholes, J. J., Wadlow, R., Wenczl, M., & Wong, M.
- Affiliations
- Taipei Veterans General Hospital (TW)
- St John of God Subiaco Hospital (AU)
- National Cheng Kung University Hospital (TW)
- Translational Genomics Research Institute (US)
- Vall d'Hebron Institute of Oncology (ES)
- Seoul National University Hospital (KR)
- Royal Marsden Hospital (GB)
- Hôpital Saint-André (FR)
- The Christie NHS Foundation Trust (GB)
- China Medical University Hospital (TW)
- Hospital de Clínicas de Porto Alegre (BR)
- TUM Klinikum (DE)
- Comprehensive Cancer Centers of Nevada (US)
- Merrimack Pharmaceuticals (United States) (US)
- Kaohsiung Medical University (TW)
- Corresponding author
- Chen, Li-Tzong
- ORCID
- Li, Chung-Pin
- Dean, Andrew
- Shan, Yan-Shen
- Jameson, Gayle
- Macarulla, Teresa
- Lee, Kyung-Hun
- Cunningham, David
- Hubner, Richard A
- Schwartsmann, Gilberto
- Siveke, Jens T
- Braiteh, Fadi
- Moyo, Victor
- Belanger, Bruce
- Chen, Li-Tzong
- Asselah, Jamil
- Barrios, Carlos Henrique
- Chang, David
- Chen, Jen-Shi
- Chen, Yeu-Chin
- Choi, Hye Jin
- Chung, Vincent
- Cubillo, Antonio
- Dragovich, Tomislav
- Fein, Luis Enrique
- Fuchs, Martin
- Korbenfeld, Ernesto
- Lee, Fa-Chyi
- Lee, Kuan-Der
- Ma, Wen Wee
- Palmer, Daniel
- Pant, Shubham
- Park, Joon Oh
- Pelzer, Uwe
- Rau, Kun-Ming
- Raoul, Jean-Luc
- Richards, Donald
- Ross, Paul
- Stahalova, Vladimira
- Sternberg, Cora
- Seufferlein, Thomas
- Tebbutt, Niall
- Wadlow, Raymond
- Wong, Mark
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2016-02
- Volume
- 387
- Issue
- 10018
- Pages
- 545-557
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2187917981
- Cited by
- 1,222
- References
- 29
- Citations by year
- 2026: 92 · 2025: 123 · 2024: 122 · 2023: 116 · 2022: 119 · 2021: 156 · 2020: 117 · 2019: 116 · 2018: 99 · 2017: 101 · 2016: 53
- FWCI
- 37.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- 5-fluorouracil, leucovorin, metastatic pancreatic ductal adenocarcinoma, gemcitabine-refractory disease, combination chemotherapy, overall survival, first-line therapy, NAPOLI-1 trial, albumin, Karnofsky performance status
- MeSH terms
- Irinotecan, Gemcitabine, Aged, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Deoxycytidine, Diarrhea, Fatigue, Female, Fluorouracil, Humans, Liposomes, Male, Middle Aged, Neoplasm Metastasis, Neutropenia, Pancreatic Neoplasms, Vomiting, Treatment Outcome, Carcinoma, Pancreatic Ductal, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
